Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial
DOI10.1038/S41591-022-01789-0WikidataQ112693484 ScholiaQ112693484MaRDI QIDQ94249FDOQ94249
Authors: Felice Rivellese, Anna E. A. Surace, Katriona Goldmann, Elisabetta Sciacca, Cankut Cubuk, Giovanni Giorli, Christopher R. John, Alessandra Nerviani, Liliane Fossati-Jimack, Georgina Thorborn, Manzoor Ahmed, Edoardo Prediletto, Sarah E Church, Briana M. Hudson, Sarah E. Warren, Paul M. Mckeigue, Frances Humby, Michele Bombardieri, Michael R. Barnes, Myles Lewis, Costantino Pitzalis, Patrick Durez, Maya H. Buch, Hasan Rizvi, Arti Mahto, Carlomaurizio Montecucco, Bernard Lauwerys, Nora Ng, Pauline Ho, Vasco C. Romão, João Eurico Cabral Da Fonseca, Patrick Verschueren, Stephen Kelly, Pier Paolo Sainaghi, Nagui Gendi, Bhaskar Dasgupta, Alberto Cauli, Piero Reynolds, Juan D. Cañete, Julio Ramirez, Raquel Celis, Robert Moots, Peter C. Taylor, Chris J. Edwards, John Isaacs, Peter Sasieni, Ernest Choy, Charlotte Thompson, Serena Bugatti, Mattia Bellan, Mattia Congia, Christopher Holroyd, Arthur Pratt, Laura White, Louise Warren, Joanna Peel, Rebecca Hands, Gaye Hadfield 
Publication date: 19 May 2022
Published in: Nature Medicine (Search for Journal in Brave)
Cited In (1)
This page was built for publication: Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q94249)
